Previous 10 | Next 10 |
Tyme Technologies ( TYME ) is moving closer to a transformative point in the company’s history. Tyme is now working on their enrollment of two pancreatic cancer pivotal trials for SM-88. If successful, these programs will bring tremendous value to the company and their shareholders. So ...
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that the Company has resubmitted its New Drug Application (“NDA”) for RYANODEX ® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke (“EHS”...
Thinly traded micro cap Tyme Technologies ( TYME +16.2% ) is up on almost an 8x surge in volume on the heels of its collaboration agreement with Eagle Pharmaceuticals ( EGRX -1.1% ) aimed at promoting lead candidate SM-88 in advanced cancers. More news on: Tyme Technologies, Inc., Ea...
Collaboration leverages combined capabilities of Tyme Technologies and Eagle Pharmaceuticals to maximize potential of oral SM-88 by advancing pivotal trials and commercialization. TYME recently launched the TYME-88-PANC pivotal trial to evaluate oral SM-88 for third-line treatment of p...
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) announced today a new research agreement with NorthShore University HealthSystem in Evanston, IL, focused on studying Eagle’s RYANODEX ® (dantrolene sodium) for traumatic brain injury (TBI) in animal models. &...
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference as follows: The pres...
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation (ODD) for RYANODEX ® (dantrolene sodium) for the treatment of organophos...
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Eli Lilly and Company (NYSE: LLY) (“Lilly”) related to the Company’s novel product, PEMFEXY™ (pemetrexe...
Eagle Pharmaceuticals (NASDAQ: EGRX) on Monday announced that it has initiated dosing in a pilot clinical study to evaluate the unique characteristics of fulvestrant, EGRX’s product candidate that has the potential to enhance estrogen receptor (“ER”) inhibition and improve...
--Product has potential to achieve greater inhibition of estrogen receptors and better outcomes for patients with ER-positive breast cancer-- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company has commenced d...
News, Short Squeeze, Breakout and More Instantly...
Eagle Pharmaceuticals Inc. Company Name:
EGRX Stock Symbol:
NASDAQ Market:
Eagle Pharmaceuticals Inc. Website:
2024-07-27 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-17 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-07 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...